Daily Endocrinology Research Analysis
Three high-impact endocrinology papers stand out today: a multi-centre randomized trial shows that replacing sugars with sweeteners supports 1-year weight-loss maintenance and shifts the gut microbiome; mechanistic work reveals that β cells use the innate immune E3 ligase TRAF6 to route mitophagy and preserve glucose homeostasis under metabolic stress; and human single-cell islet analyses identify SMOC1 as a driver of β-cell dedifferentiation toward α-like states in type 2 diabetes.
Summary
Three high-impact endocrinology papers stand out today: a multi-centre randomized trial shows that replacing sugars with sweeteners supports 1-year weight-loss maintenance and shifts the gut microbiome; mechanistic work reveals that β cells use the innate immune E3 ligase TRAF6 to route mitophagy and preserve glucose homeostasis under metabolic stress; and human single-cell islet analyses identify SMOC1 as a driver of β-cell dedifferentiation toward α-like states in type 2 diabetes.
Research Themes
- Metabolic stress adaptations in β cells via mitophagy and innate immune signaling
- Dietary sweeteners and long-term weight-loss maintenance with gut microbiome shifts
- Islet cell plasticity and β-to-α-cell dedifferentiation mechanisms in type 2 diabetes
Selected Articles
1. TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and Parkin-independent mitophagy.
Using mouse and human islets under metabolic stress, the authors show that the E3 ligase TRAF6 is essential for insulin secretion, mitochondrial respiration, and mitophagy. TRAF6 coordinates Parkin-dependent mitophagy; intriguingly, Parkin deletion rescues the glucose intolerance caused by TRAF6 loss by alleviating a block in receptor-mediated mitophagy. These findings position innate immune signaling via TRAF6 as an adaptive β-cell mechanism in diabetogenic environments.
Impact: This study uncovers a cross-regulatory node between ubiquitin- and receptor-mediated mitophagy that maintains β-cell function under metabolic stress, resolving a key question in immunometabolic adaptation.
Clinical Implications: Targeting the TRAF6–mitophagy axis could preserve β-cell function in type 2 diabetes, and mitophagy pathway status may guide therapeutic stratification.
Key Findings
- TRAF6 is dispensable at baseline but required for insulin secretion, mitochondrial respiration, and mitophagy after metabolic stress in mouse and human islets.
- TRAF6 is critical for recruitment and function of Parkin-dependent mitophagy machinery.
- Glucose intolerance due to TRAF6 deficiency under metabolic stress is reversed by Parkin deficiency, relieving a block in receptor-mediated mitophagy.
Methodological Strengths
- Integrated mouse genetics and human islet studies with functional readouts (insulin secretion, respiration, mitophagy).
- Mechanistic dissection of Parkin-dependent vs receptor-mediated mitophagy using loss-of-function epistasis.
Limitations
- Preclinical mechanistic study; translational relevance requires validation in humans in vivo.
- β-cell–specific effects under diet-induced obesity may not generalize across all T2D contexts.
Future Directions: Test pharmacologic modulation of TRAF6/mitophagy in diabetic models; define biomarkers of mitophagy pathway engagement in human T2D.
Innate immune signaling is activated in immunometabolic diseases, including type 2 diabetes, yet its impact on glucose homeostasis is controversial. Here, we report that the E3 ubiquitin ligase TRAF6 integrates innate immune signals following diet-induced obesity to promote glucose homeostasis through the induction of mitophagy. Whereas TRAF6 was dispensable for pancreatic β cell function at baseline, TRAF6 was pivotal for insulin secretion, mitochondrial respiration, and mitophagy following metabolic stress in mouse and human islets. TRAF6 was critical for the recruitment and function of the ubiquitin-mediated (Parkin-dependent) mitophagy machinery. Glucose intolerance induced by TRAF6 deficiency following metabolic stress was reversed by concomitant Parkin deficiency by relieving obstructions in receptor-mediated (Parkin-independent) mitophagy. Our results establish that TRAF6 is vital for traffic through Parkin-mediated mitophagy and implicates TRAF6 in the cross-regulation of ubiquitin- and receptor-mediated mitophagy. Together, we illustrate that β cells engage innate immune signaling to adaptively respond to a diabetogenic environment.
2. Effect of sweeteners and sweetness enhancers on weight management and gut microbiota composition in individuals with overweight or obesity: the SWEET study.
In a multi-centre randomized trial (NCT04226911), replacing sugar with sweeteners and sweetness enhancers helped adults with overweight/obesity maintain greater weight loss over 1 year and shifted the gut microbiome toward SCFA- and methane-producing taxa. No significant cardiometabolic differences were detected and pediatric outcomes were neutral, supporting safety in this context.
Impact: Provides randomized evidence resolving controversy about long-term use of sweeteners in weight maintenance and links outcomes to microbiome shifts.
Clinical Implications: Clinicians can consider S&SEs as part of a healthy diet to support weight-loss maintenance without adverse cardiometabolic signals over 1 year; microbiome shifts may serve as mechanistic biomarkers.
Key Findings
- Adults assigned to S&SEs maintained 1.6 ± 0.7 kg greater weight loss at 1 year versus sugar (P = 0.029).
- Gut microbiota showed increased SCFA- and methane-producing taxa (q ≤ 0.05) in the S&SEs group.
- No significant differences were observed in cardiometabolic markers, and pediatric outcomes were neutral.
Methodological Strengths
- Multi-centre randomized controlled design with predefined primary outcomes and 1-year follow-up.
- Integration of microbiome profiling with clinical weight outcomes.
Limitations
- Effect size for weight maintenance was modest; trial likely open-label with potential behavioral biases.
- Pediatric sample was small and cardiometabolic endpoints showed no differences.
Future Directions: Define dose–response and sweetener classes, assess longer-term cardiometabolic outcomes, and mechanistically link microbiome changes to energy balance.
Consumption of sweeteners and sweetness enhancers (S&SEs) is a popular strategy to reduce sugar intake, but the role of S&SEs in body weight regulation and gut microbiota composition remains debated. Here, we show that S&SEs in a healthy diet support weight loss maintenance and beneficial gut microbiota shifts in adults with overweight or obesity. In this multi-centre, randomized, controlled trial, we included 341 adults and 38 children with overweight or obesity. Adults followed a 2-month low-energy diet for ≥5% weight loss, followed by a 10-month healthy ad libitum diet with <10% energy from sugars. One group replaced sugar-rich products with S&SE products (S&SEs group), while the other did not (sugar group). Primary outcomes included changes in body weight and gut microbiota composition at 1 year. Secondary outcomes included changes in cardiometabolic parameters. The S&SEs group, compared to the sugar group, maintained greater weight loss at 1 year (1.6 ± 0.7 kg, P = 0.029) and exhibited distinct gut microbiota shifts, with increased short-chain fatty acid and methane-producing taxa (q ≤ 0.05). No significant differences were observed in cardiometabolic markers or in children. Overall, our findings indicate that prolonged consumption of S&SEs in a healthy diet is a safe strategy for obesity management. ClinicalTrial.gov identifier: NCT04226911 .
3. Human pancreatic α-cell heterogeneity and trajectory inference analyses reveal SMOC1 as a β-cell dedifferentiation gene.
Single-cell and trajectory analyses of human islets identified five α-cell subclusters and revealed unidirectional β-to-α trajectories in type 2 diabetes. SMOC1 emerged as a key signature gene aberrantly expressed in β cells in T2D; its overexpression reduced insulin expression/secretion and increased dedifferentiation markers, nominating SMOC1 as a causal driver.
Impact: Defines α-cell heterogeneity and a β-to-α dedifferentiation path in human T2D islets, and pinpoints SMOC1 as a tractable gene target for reversing β-cell failure.
Clinical Implications: SMOC1 could serve as a biomarker of β-cell dedifferentiation and a therapeutic target to preserve or restore β-cell identity and function in type 2 diabetes.
Key Findings
- Five α-cell subclusters with distinct transcriptomes were identified in human islets.
- Non-diabetic islets showed bifurcating trajectories, whereas T2D islets showed unidirectional β-to-α trajectories consistent with dedifferentiation.
- SMOC1 was aberrantly expressed in β cells in T2D; its overexpression reduced insulin expression/secretion and increased dedifferentiation markers.
Methodological Strengths
- Integrated single-cell/single-nucleus RNA-seq with RNA velocity and PAGA trajectory inference.
- Functional validation showing causal effects of SMOC1 on β-cell identity and insulin secretion.
Limitations
- Functional studies were primarily in vitro; in vivo validation is needed.
- Human sampling is cross-sectional; longitudinal fate mapping in humans is not feasible.
Future Directions: Test SMOC1 inhibition in human islet models and animal systems; evaluate SMOC1 as a circulating biomarker of β-cell dedifferentiation.
β-cell dysfunction and dedifferentiation towards an α-cell-like phenotype are hallmarks of type 2 diabetes. However, the cell subtypes involved in β-to-α-cell transition are unknown. Using single-cell and single-nucleus RNA-seq, RNA velocity, PAGA/cell trajectory inference, and gene commonality, we interrogated α-β-cell fate switching in human islets. We found five α-cell subclusters with distinct transcriptomes. PAGA analysis showed bifurcating cell trajectories in non-diabetic while unidirectional cell trajectories from β-to-α-cells in type 2 diabetes islets suggesting dedifferentiation towards α-cells. Ten genes comprised the common signature genes in trajectories towards α-cells. Among these, the α-cell gene SMOC1 was expressed in β-cells in type 2 diabetes. Enhanced SMOC1 expression in β-cells decreased insulin expression and secretion and increased β-cell dedifferentiation markers. Collectively, these studies reveal differences in α-β-cell trajectories in non-diabetes and type 2 diabetes human islets, identify signature genes for β-to-α-cell trajectories, and discover SMOC1 as an inducer of β-cell dysfunction and dedifferentiation.